SCHEMBL2734735

SCHEMBL2734735

CCCCCCCCCCCCCC=CC(O)C(CO)NC(=O)CCCCCCC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CETP P11597 4/20 1.00
THRB P10828 1/20 1.00
MEN1 O00255 1/20 1.00
KMT2A Q03164 1/20 1.00
ASAH1 Q13510 2/20 0.78
TP53 P04637 2/20 0.75
CYP1A2 P05177 1/20 0.75
CYP2D6 P10635 1/20 0.75
MAPT P10636 1/20 0.75
CYP2C9 P11712 1/20 0.75
MAPK1 P28482 1/20 0.75
CYP2C19 P33261 1/20 0.75
ASAH2 Q9NR71 2/20 0.71
DEGS1 O15121 1/20 0.70
PLA2G4A P47712 4/20 0.68
ALDH1A1 P00352 2/20 0.64
KDM4E B2RXH2 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4133213 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL13863420 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL22973496 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL5527047 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL22911186 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL22973426 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL24032894 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL22973497 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL22910831 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL22910800 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151073-A1 COMPOSITION AND NANOPARTICLE SUITABLE FOR USE IN THE DELIVERY OF A THERAPEUTIC AGENT AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2025-07-17 WO claimed
EP-4584278-A1 2-AMINOPROPANE-1,3-DIOL-CAPPED CATIONIC PEPTOIDS FOR NUCLEIC ACID DELIVERY Nutcracker Therapeutics, Inc. (US) 2025-07-16 EP claimed
WO-2025137277-A1 DEGRADABLE PEPTOIDS NUTCRACKER THERAPEUTICS, INC. (US) 2025-06-26 WO claimed
US-20240307526-A1 COMPOSITIONS COMPRISING HYDROXYETHYL-CAPPED CATIONIC PEPTOIDS MEDICI THERAPEUTICS, INC. 2024-09-19 US claimed
CN-118320191-A Drug coated balloon catheter for non-vascular stenosis 优敦力公司 2024-07-12 CN claimed
CN-118236560-A Drug coated balloon catheter for non-vascular stenosis 优敦力公司 2024-06-25 CN claimed
EP-4380949-A1 COMPOSITIONS COMPRISING HYDROXYETHYL-CAPPED CATIONIC PEPTOIDS Nutcracker Therapeutics, Inc. (US) 2024-06-12 EP claimed
WO-2024054617-A1 2-AMINOPROPANE-1,3-DIOL-CAPPED CATIONIC PEPTOIDS FOR NUCLEIC ACID DELIVERY NUTCRACKER THERAPEUTICS, INC. (US) 2024-03-14 WO claimed
EP-4228667-A1 METHODS FOR REVERSING HEPATIC STEATOSIS Brightseed, Inc. (US) 2023-08-23 EP claimed
US-11679165-B2 Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-06-20 US claimed
CN-108845051-B Method for detecting sphingolipid in zebra fish brain tissue based on UHPLC-QTrap MS 中国农业科学院农业质量标准与检测技术研究所 2021-07-06 CN claimed
CN-111281851-A PH-targeted flexible nanoliposome with acne removing effect and preparation method thereof 程定义 2020-06-16 CN claimed
EP-3562510-A1 BRANCHED PEG MOLECULES AND RELATED COMPOSITIONS AND METHODS Genevant Sciences GmbH (CH) 2019-11-06 EP claimed
WO-2018126084-A1 BRANCHED PEG MOLECULES AND RELATED COMPOSITIONS AND METHODS PHASERX, INC. (US) 2018-07-05 WO claimed
EP-1250119-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2007-10-03 EP claimed
EP-1250119-A2 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2002-10-23 EP claimed
WO-2001054654-A2 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2001-08-02 WO claimed
US-6235737-B1 APPLYING COMPOUND TO ADJUST CERAMIDE CONCENTRATION GILLETTE COMPANY, THE 2001-05-22 US claimed
EP-0850056-A1 TOPICAL ANTI-SKIN-CANCER PREPARATIONS Beiersdorf Aktiengesellschaft (DE) 1998-07-01 EP claimed
WO-1997009975-A1 TOPICAL ANTI-SKIN-CANCER PREPARATIONS BEIERSDORF AG (DE) 1997-03-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11679165-B2 Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof UGT1A10, AKR1B10, CCR10 CETP 1182/4885THRB 3261/4885MEN1 1931/4885
US-20240307526-A1 COMPOSITIONS COMPRISING HYDROXYETHYL-CAPPED CATIONIC PEPTOIDS TLR9, TLR3, MICA CETP 121/4885THRB 4504/4885MEN1 3541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.